Currently, the global alopecia market has very limited approved therapies with two being global and one being approved only for Japan, South Korea, and Australia. Consequently, the market relies heavily on off-label and over-the-counter (OTC) drugs, which form large volume sales but add less to the market value. In spite of the unknown pathophysiology of this condition, the current pipeline looks promising, especially due to novel Janus kinase (JAK) inhibitor, SM04554. As this commands higher efficacy and safety as per the clinical trials, once launched, will be one of the primary growth drivers. Regenerative medicines will be the next wave of growth in global alopecia drugs market. The advent of cell therapy and tissue engineering will be able to overcome the barrier of complete hair restoration, which remains a challenge otherwise,through therapeutic usage. The competition, going forward, will become intense for prominent vendors in current alopecia therapeutic market such as Merck and Johnson & Johnson and could result into sales erosion of their drugs as well once regenerative vendors such as RepliCel gets the approval for its Phase II molecule.

PART 01: Executive summary 7
Highlights 7
PART 02: Scope of the report 8
Market overview 8
Top-vendor offerings 10
PART 03: Market research methodology 11
Research methodology 11
Economic indicators 11
PART 04: Introduction 12
Key market highlights 12
PART 05: Overview: Alopecia 13
Causes of hair loss 13
Hair loss: Symptoms and treatment 15
PART 06: Pipeline portfolio 16
PART 07: Market landscape 19
Market overview 19
Five forces analysis 26
PART 08: Key buying criteria 27
PART 09: Market segmentation by ROA 30
Global topical alopecia drugs market 32
Global oral alopecia drugs market 33
Global injectable alopecia drugs market 34
PART 10: Market segmentation by gender 35
PART 11: Geographical segmentation 36
Alopecia drugs market in Americas 38
Alopecia drugs market in EMEA 40
Alopecia drugs market in APAC 42
PART 12: Market drivers 44
Lifestyle changes 44
Popularity of off-label and OTC drugs 45
High uptake of approved therapies 47
PART 13: Impact of drivers 49
PART 14: Market challenges 50
Poor patient adherence 50
Preference for alternative therapies 50
Limited approved therapies 52
PART 15: Impact of drivers and challenges 53
PART 16: Market trends 54
Focus on regenerative medicines 54
Emergence of laser technology and PRP therapy 55
Launch of new products 57
PART 17: Vendor landscape 58
Competitive scenario 58
Other prominent vendors 60
PART 18: Key vendor analysis 66
GlaxoSmithKline 66
Johnson & Johnson 68
Merck 70
PART 19: Appendix 74
List of abbreviations 74
PART 20: Explore Technavio 7